Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Joe Copia's daytrades/investments and thoughts -- Ignore unavailable to you. Want to Upgrade?

To: RCJIII who wrote (13113)	3/9/1999 12:36:00 PM
From: Joe Copia	Respond to of 25711

ZKEM news: Tuesday March 9, 11:22 am Eastern Time Company Press Release Xechem Announces Issuance of U.S. Patent No. 5,854,278 for Paclitaxel Analogs With Demonstrated Increased Efficacy Against Certain Tumors NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--March 9, 1999--Xechem International Inc. (OTC BB: ZKEM) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 5,854,278 containing broad coverage with respect to several novel paclitaxel analogs developed by Xechem. Preliminary studies have shown strong anti-neoplastic efficacy of these compounds against a wide array of cancer tumor cells and leukemic cells rivaling, and in certain instances, significantly outperforming paclitaxel (marketed by Bristol-Myers Squibb under its Taxol® trademark) and Rhone Poulenc Rohrer's Taxotere® analog. These analogs are produced by semisynthesis involving selective halogenation of paclitaxel's close analog cephalomannine, to produce dihaloisomers of cephalomannine including (2''R, 3''S) and (2''S, 3''R) dichlorocephalomannine, (2''R, 3''S) and (2''S, 3''R) dichloro 7-epi-cephalomannine. In addition to the novel paclitaxel analogs, this patent contains claims which very broadly cover pharmaceutical formulations comprising the aforesaid compounds, a method for administering the compounds for treating both animal and human tumors, and a method for production of the novel compounds. According to Xechem's President and CEO, Dr. Ramesh Pandey, We are excited and pleased with the breadth of Xechem's rapidly increasing patent portfolio for paclitaxel analogs, which now cover several potentially new pharmaceuticals, all of which have been shown to possess anticancer activity against a wide array of tumors. Xechem's new cancer drug products have been shown to be more physiologically soluble and may prove to offer viable alternatives to paclitaxel without its deleterious side effects. This will be the seventh patent in this important area granted to Xechem. Our hard work is coming to fruition. Xechem is a bio-pharmaceutical company engaged in the research, development and production of generic and proprietary drugs from natural sources, specializing in the development of difficult to replicate anticancer, antiviral (including AIDS) and antifungal compounds. The Company also screens compounds for therapeutic action from China and India. For further information, contact Xechem's President and Chief Executive Officer, Dr. Ramesh C. Pandey 732/247-3300. This news release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks, uncertainties, including the ability of the Companies to successfully develop and commercialize their technologies, and other factors that may cause the actual results, performance or achievements of the Companies to be materially different from any future results, performance or achievements of the Companies expressed or implied by such forward-looking statements. Contact: Xechem International Inc. Dr. Ramesh C. Pandey, 732/247-3300